HealthModerna and Merck's Breakthrough Melanoma Vaccine Revives Promise for mRNA Technology
A late-stage trial by Moderna and Merck shows their personalised mRNA melanoma vaccine successfully reduces cancer recurrence when combined with Keytruda, marking a major milestone for the technology.
The National|August 20, 2026 